October 26, 2026- Abbott announced the commercial availability of its next-generation Oncodetect® MRD test, a personalized, tumor-informed, whole-genome sequencing test designed to provide molecular insights during and after cancer treatment. For more than 20 years, the Oncotype DX Breast Recurrence Score® test has helped physicians use genomic information to personalize breast cancer treatment and is recognized as a standard of care in early-stage breast cancer. The next-generation Oncodetect test builds on that foundation, expanding Abbott’s ability to provide molecular insights across the cancer care continuum. The personalized test uses a sample of each patient’s tumor to identify its unique DNA markers, then looks for those same signals in the blood.